CardioVascular and Interventional Radiology

, Volume 30, Issue 2, pp 155–160 | Cite as

Lipid-Altering Therapies and the Progression of Atherosclerotic Disease

  • Anthony S. WierzbickiEmail author


Lipids play a key role in the progression of atherosclerosis, and lipid-lowering therapies have been studied for 30 years in coronary disease. Measurement of the progression of atherosclerosis through carotid intima-media thickness, coronary mean lumen diameter, and, mostly recently, intravascular ultrasound is generally accepted. This article reviews the role of lipid-lowering therapies in changing the rate of atherosclerosis progression in the coronary and carotid circulations. Statins are the primary therapy used to reduce atherosclerosis and cardiovascular events, including strokes and transient ischemic attacks, and have benefits in reducing events in patients undergoing carotid endarterectomy. In contrast, data for other agents, including fibrates and nicotinic acid, in reducing the progression of atherosclerosis are less extensive and not as well known. There is increasing interest in optimizing the whole lipid profile, as this might deliver extra benefits over and above statin therapy alone. Initial proof of this concept has recently come from studies that measured the progression of atherosclerosis and showed that adding nicotinic acid to statin therapy and, more directly, infusion of high-density lipoprotein-like particles reduced progression and indeed might induce regression of the disease. It is likely that the management of significant carotid stenosis will become ever more drug focused and will be customized to the lipid profile of each patient with intervention reserved only for late-stage symptomatic disease.


Atherosclerosis Statin Cholesterol Interventional radiology Intravascular ultrasound Intima-media thickness Stroke Peripheral vascular disease HDL cholesterol LDL cholesterol 



This review is based on a talk given at the Annual Congress of Cardiovascular and Interventional Radiological Society of Europe in Nice 2005. Dr. Wierzbicki has received honoraria for lectures and advisory boards as well as travel and research grants from Astra-Zeneca, Bristol-Myers-Squibb, GlaxoSmithKline, Merck kGA, Merck, Sharp & Dohme, Novartis, Pfizer, Sanofi-Aventis, Schering-Plough, Solvay-Fournier, and Takeda.


  1. 1.
    Yusuf S, Hawken S, Ounpuu S, et al. (2004) Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. Lancet 364(9438): 937–952PubMedCrossRefGoogle Scholar
  2. 2.
    Rothwell PM, Coull AJ, Giles MF, et al. (2004) Change in stroke incidence, mortality, case-fatality, severity, and risk factors in Oxfordshire, UK from 1981 to 2004 (Oxford Vascular Study). Lancet 363(9425): 1925–1933PubMedCrossRefGoogle Scholar
  3. 3.
    Atkins D, Psaty BM, Koepsell TD, et al. (1993) Cholesterol reduction and the risk for stroke in men. A meta-analysis of randomized, controlled trials. Ann Intern Med 119(2): 136–145PubMedGoogle Scholar
  4. 4.
    Glagov S, Weisenberg E, Zarins CK, et al. (1987) Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med 316(22): 1371–1375PubMedCrossRefGoogle Scholar
  5. 5.
    Davies MJ (1998) Coronary artery remodelling and the assessment of stenosis by pathologists. Histopathology 33(6): 497–500PubMedCrossRefGoogle Scholar
  6. 6.
    Falk E, Shah PK, Fuster V (1995) Coronary plaque disruption. Circulation 92(3): 657–671PubMedGoogle Scholar
  7. 7.
    Espeland MA, O’Leary DH, Terry JG, et al. (2005) Carotid intimal-media thickness as a surrogate for cardiovascular disease events in trials of HMG-CoA reductase inhibitors. Curr Control Trials Cardiovasc Med 6(1): 3PubMedCrossRefGoogle Scholar
  8. 8.
    Spence JD (2002) Ultrasound measurement of carotid plaque as a surrogate outcome for coronary artery disease. Am J Cardiol 89(4A): 10B–15BPubMedCrossRefGoogle Scholar
  9. 9.
    Nissen SE (2002) Application of intravascular ultrasound to characterize coronary artery disease and assess the progression or regression of atherosclerosis. Am J Cardiol 89(4A): 24B–31BPubMedCrossRefGoogle Scholar
  10. 10.
    Davies MJ, (1995) Acute coronary thrombosis: The role of plaque disruption and its initiation and prevention. Eur Heart J 16( Suppl L): 3–7PubMedGoogle Scholar
  11. 11.
    Keys A, Menotti A, Aravanis C, et al. (1984) The seven countries study: 2,289 deaths in 15 years. Prev Med 13(2): 141–154PubMedCrossRefGoogle Scholar
  12. 12.
    Buchwald H, Matts JP, Fitch LL, et al. (1992) Changes in sequential coronary arteriograms and subsequent coronary events. Surgical Control of the Hyperlipidemias (POSCH) Group. JAMA 1268(11): 1429–1433CrossRefGoogle Scholar
  13. 13.
    Watts GF, Lewis B, Brunt JN, et al. (1992) Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas’ Atherosclerosis Regression Study (STARS). Lancet 339(8793): 563–569PubMedCrossRefGoogle Scholar
  14. 14.
    Plehn JF, Davis BR, Sacks FM, et al. (1999) Reduction of stroke incidence after myocardial infarction with pravastatin: The Cholesterol and Recurrent Events (CARE) study. The Care Investigators. Circulation 99(2): 216–223PubMedGoogle Scholar
  15. 15.
    Byington RP, Davis BR, Plehn JF, et al. (2001) Reduction of stroke events with pravastatin: The Prospective Pravastatin Pooling (PPP) Project. Circulation 103(3): 387–392PubMedGoogle Scholar
  16. 16.
    Byington RP, Jukema JW, Salonen JT, et al. (1995) Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program. Circulation 92(9): 2419–2425PubMedGoogle Scholar
  17. 17.
    Athyros VG, Papageorgiou AA, Mercouris BR, et al. (2002) Treatment with Atorvastatin to the National Cholesterol Educational Program Goals versus Usual Care in Secondary Coronary Heart Disease Prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. Curr Med Res Opin 18(4): 220–228PubMedCrossRefGoogle Scholar
  18. 18.
    Bucher HC, Griffith LE, Guyatt GH (1999) Systematic review on the risk and benefit of different cholesterol-lowering interventions. Arterioscler Thromb Vasc Biol 19(2): 187–195PubMedGoogle Scholar
  19. 19.
    Baigent C, Keech A, Kearney PM, et al. (2005) Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366(9493): 1267–1278PubMedCrossRefGoogle Scholar
  20. 20.
    Grundy SM (2005) The changing face of cardiovascular risk. J Am Coll Cardiol 46(1): 173–175PubMedCrossRefGoogle Scholar
  21. 21.
    Byington RP, Furberg CD, Crouse JR, III, et al. (1995) Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II). Am J Cardiol 76(9): 54C–59CPubMedCrossRefGoogle Scholar
  22. 22.
    Salonen R, Nyyssonen K, Porkkala E, et al. (1995) Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation 92(7): 1758–1764PubMedGoogle Scholar
  23. 23.
    Nissen SE, Tuzcu EM, Schoenhagen P, et al. (2004) Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: A randomized controlled trial. JAMA 291(9): 1071–1080PubMedCrossRefGoogle Scholar
  24. 24.
    Nissen SE, Nicholls SJ, Sipahi I, et al. (2006) Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: The ASTEROID trial. JAMA 295(13): 1556–1565PubMedCrossRefGoogle Scholar
  25. 25.
    Pyorala K, Ballantyne CM, Gumbiner B, et al. (2004) Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: Subgroup analyses of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 27(7): 1735–1740PubMedGoogle Scholar
  26. 26.
    Collins R, Armitage J, Parish S, et al. (2004) Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 363(9411): 757–767PubMedCrossRefGoogle Scholar
  27. 27.
    Nickenig G, Baumer AT, Temur Y, et al. (1999) Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation 100(21): 2131–2134PubMedGoogle Scholar
  28. 28.
    Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. (2004) Effect of statins and ACE inhibitors alone and in combination on clinical outcome in patients with coronary heart disease. J Hum Hypertens 18(11): 781–788PubMedCrossRefGoogle Scholar
  29. 29.
    Poulter N, Sever PS (2004) Do statins lower blood pressure? Evidence from the Anglo-Scandinavian Cardiac Outcomes Trial- Lipid-Lowering Arm (ASCOT-LLA). Circulation 110(Suppl III): III–402 (abstract 1905)Google Scholar
  30. 30.
    Goode GK, Miller JP, Heagerty AM (1995) Hyperlipidaemia, hypertension, and coronary heart disease. Lancet 345(8946): 362–364PubMedCrossRefGoogle Scholar
  31. 31.
    Wierzbicki AS (2002) Lipid lowering: Another method of reducing blood pressure? J Hum Hypertens 16(11): 753–760PubMedCrossRefGoogle Scholar
  32. 32.
    Wierzbicki AS (2006) Statins and hypertension. J Hum Hypertens 20(8): 551–553CrossRefGoogle Scholar
  33. 33.
    Goode GK, Miller JP, Heagerty AM (1995) Hyperlipidaemia, hypertension, and coronary heart disease. Lancet 345: 362–364PubMedCrossRefGoogle Scholar
  34. 34.
    Tonelli M, Sacks F, Pfeffer M, et al. (2006) Effect of pravastatin on blood pressure in people with cardiovascular disease. J Hum Hypertens 20(8): 560–565PubMedCrossRefGoogle Scholar
  35. 35.
    Wierzbicki AS, Mikhailidis DP, Reynolds TM (2003) More on PROSPER. Lancet 361(9363): 1135–1136PubMedCrossRefGoogle Scholar
  36. 36.
    Shepherd J, Blauw GJ, Murphy MB, et al. (2002) Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial. Lancet 360(9346): 1623–1630PubMedCrossRefGoogle Scholar
  37. 37.
    Watts GF, Lewis B, Brunt JN, et al. (1992) Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas’ Atherosclerosis Regression Study (STARS). Lancet 339(8793): 563–569PubMedCrossRefGoogle Scholar
  38. 38.
    Diabetes Atherosclerosis Intervention Study Group (2001) Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: The Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 357(9260):905–910CrossRefGoogle Scholar
  39. 39.
    Taylor AJ, Sullenberger LE, Lee HJ, et al. (2004) Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2. A double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 110(23):3512–3517PubMedCrossRefGoogle Scholar
  40. 40.
    Wierzbicki AS, Mikhailidis DP (2002) Beyond LDL-C: The importance of raising HDL-C. Curr Med Res Opin 18(1): 36–44PubMedCrossRefGoogle Scholar
  41. 41.
    Chapman MJ, Assmann G, Fruchart JC, et al. (2004) Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: The role of nicotinic acid—A position paper developed by the European Consensus Panel on HDL-C. Curr Med Res Opin 20(8): 1253–1268PubMedCrossRefGoogle Scholar
  42. 42.
    Wierzbicki AS, Mikhailidis DP, Wray R (2001) Drug treatment of combined hyperlipidemia. Am J Cardiovasc Drugs 1(5): 327–336PubMedCrossRefGoogle Scholar
  43. 43.
    Karpe F, Frayn KN (2004) The nicotinic acid receptor: A new mechanism for an old drug. Lancet 363(9424): 1892–1894PubMedCrossRefGoogle Scholar
  44. 44.
    Whitney EJ, Krasuski RA, Personius BE, et al. (2005) A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: Effects on progression of coronary heart disease and clinical events. Ann Intern Med 142(2): 95–104PubMedGoogle Scholar
  45. 45.
    Canner PL, Berge KG, Wenger NK, et al. (1986) Fifteen year mortality in Coronary Drug Project patients: Long-term benefit with niacin. J Am Coll Cardiol 8(6): 1245–1255PubMedCrossRefGoogle Scholar
  46. 46.
    Rubins HB, Robins SJ, Collins D, et al. (1999) Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 141(6): 410–418CrossRefGoogle Scholar
  47. 47.
    Frick MH, Elo O, Haapa K, et al. (1987) Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 317(20): 1237–1245PubMedCrossRefGoogle Scholar
  48. 48.
    Sacks FM (2002) The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: Expert group recommendations. Am J Cardiol 90(2): 139–143PubMedCrossRefGoogle Scholar
  49. 49.
    Wierzbicki AS (2005) Have we forgotten the pivotal role of high-density lipoprotein cholesterol in atherosclerosis prevention? Curr Med Res Opin 21(2): 299–306PubMedCrossRefGoogle Scholar
  50. 50.
    Frick MH, Syvanne M, Nieminen MS, et al. (1997) Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group. Circulation 96(7): 2137–2143PubMedGoogle Scholar
  51. 51.
    Ericsson CG, Hamsten A, Nilsson J, et al. (1996) Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 347(9005): 849–853PubMedCrossRefGoogle Scholar
  52. 52.
    Keech A, Simes RJ, Barter P, et al. (2005) Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial. Lancet 366(9500): 1849–1861PubMedCrossRefGoogle Scholar
  53. 53.
    Wierzbicki AS (2006) FIELDS of dreams, fields of tears: A perspective on the fibrate trials. Int J Clin Pract 60(4): 442–449PubMedCrossRefGoogle Scholar
  54. 54.
    Chapman MJ (2006) Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease. Pharmacol Ther 111(3):893–908PubMedCrossRefGoogle Scholar
  55. 55.
    Nissen SE, Tsunoda T, Tuzcu EM, et al. (2003) Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 290(17): 2292–2300PubMedCrossRefGoogle Scholar
  56. 56.
    Wierzbicki AS (2004) Lipid-altering agents: the future. Int J Clin Pract 58(11): 1063–1072PubMedCrossRefGoogle Scholar
  57. 57.
    Barter PJ, Kastelein JJ (2006) Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease. J Am Coll Cardiol 47(3): 492–499PubMedCrossRefGoogle Scholar
  58. 58.
    Kennedy J, Quan H, Buchan AM, et al. (2005) Statins are associated with better outcomes after carotid endarterectomy in symptomatic patients. Stroke 36(10): 2072–2076PubMedCrossRefGoogle Scholar
  59. 59.
    Yokoi H, Nobuyoshi M, Mitsudo K, et al. (2005) Three-year follow-up results of angiographic intervention trial using an HMG-CoA reductase inhibitor to evaluate retardation of obstructive multiple atheroma (ATHEROMA) study. Circ J 69(8): 875–883PubMedCrossRefGoogle Scholar
  60. 60.
    Herd JA (1998) The lipoprotein and coronary atherosclerosis study (LCAS): Lipid and metabolic factors related to atheroma and clinical events. Am J Med 104(6A) 42S–49SPubMedCrossRefGoogle Scholar
  61. 61.
    Multicenter Anti-Atheroma Study Investigators (1994) Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet 344(8923):633–638CrossRefGoogle Scholar
  62. 62.
    Blankenhorn DH, Azen SP, Kramsch DM, et al. (1993) Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med 1119(10): 969–976Google Scholar
  63. 63.
    Pitt B, Mancini GB, Ellis SG, et al. (1995) Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): Reduction in atherosclerosis progression and clinical events. PLAC I investigation. J Am Coll Cardiol 26(5): 1133–1139PubMedCrossRefGoogle Scholar
  64. 64.
    Jukema JW, Bruschke AV, van Boven AJ, et al. (1995) Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation 91(10): 2528–2540PubMedGoogle Scholar
  65. 65.
    Nissen SE, Tuzcu EM, Libby P, et al. (2004) Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: The CAMELOT study: A randomized controlled trial. JAMA 292(18): 2217–2225PubMedCrossRefGoogle Scholar
  66. 66.
    Nissen SE, Tuzcu EM, Brewer HB, et al. (2006) Effect of ACAT inhibition on the progression of coronary atherosclerosis. N Engl J Med 354(12): 1253–1263PubMedCrossRefGoogle Scholar
  67. 67.
    Tardif JC, Gregoire J, L’Allier PL, et al. (2004) Effects of the acyl coenzyme A:cholesterol acyltransferase inhibitor avasimibe on human atherosclerotic lesions. Circulation 110(21): 3372–3377PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2007

Authors and Affiliations

  1. 1.Department of Chemical PathologySt. Thomas’ HospitalLondonUK

Personalised recommendations